• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Mainz Biomed N.V. - Ordinary Shares (NQ: MYNZ )

    0.2500 -0.0267 (-9.65%)
    Streaming Delayed Price Updated: 4:00 PM EST, Nov 13, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 6,902,942
    Open 0.2600
    Bid (Size) 0.2353 (19)
    Ask (Size) 0.2429 (1,893)
    Prev. Close 0.2767
    Today's Range 0.2300 - 0.2766
    52wk Range 0.1852 - 1.790
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    The Oncology Bet Is Already Paying Off For Pfizer
    With the downfall of Covid-19, pharmaceutical companies turned to oncology in search for their next growth story. Earlier in October, Pfizer Inc (NYSE: PFE) reported its third quarter revenue grew 14%... 
    Via Benzinga
    Exposures COVID-19
    Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening
    Healthcare Giant Thermo Fisher Scientific Inc. (NYSE: TMO) Inks Deal With Mainz Biomed (NASDAQ: MYNZ) To Develop And Commercialize Next Gen Colorectal Cancer Screening 
    Via News Direct

    Performance

    YTD
    -78.63%
    -78.63%
    1 Month
    -21.88%
    -21.88%
    3 Month
    -20.63%
    -20.63%
    6 Month
    -60.82%
    -60.82%
    1 Year
    -79.51%
    -79.51%

    More News

    Read More
    Mainz Biomed and Thermo Fisher Scientific Sign a Collaboration Agreement for the Development of Next Generation Colorectal Cancer Screening Product for Global Markets
    From Mainz BioMed NV
    Via GlobeNewswire
    What Mainz Biomed (NASDAQ: MYNZ) Has Been Up To Recently And Why Frankie Muniz Is A Backer
    Via News Direct
    Exposures Product Safety
    Mainz Biomed Reports Mid-Year 2024 Financial Results and Provides Corporate Update
    From Mainz BioMed NV
    Via GlobeNewswire
    12 Health Care Stocks Moving In Tuesday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Tuesday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Intraday Session
    Via Benzinga
    Personalized Treatment And Immunotherapy Are Pharma's Newest Weapons Against Cancer
    Via Benzinga
    Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
    From Mainz BioMed NV
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    Former Senior Advisor To Obama Joins Forces With Innovative Biotech To Catch Cancer Early
    Via News Direct
    The Covid Era Tech Promises To Reinvent Cancer Treatment
    Via Benzinga
    Exposures COVID-19
    Mainz Biomed Publishes CEO Statement; CEO Guido Baechler Eyes Major Growth and U.S. FDA Trials in 2025
    From Mainz BioMed NV
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    Pfizer Advances On Its Cancer Journey
    Via Benzinga
    Mainz Biomed Announces Petra Smeltzer Starke to Join Company as Brand Ambassador
    From Mainz BioMed NV
    Via GlobeNewswire
    Mainz Biomed (NASDAQ: MYNZ) And Liquid Biosciences Team Up To Fight Pancreatic Cancer With Early Detection Tool
    Via News Direct
    Topics Artificial Intelligence
    Exposures Artificial Intelligence
    Mainz Biomed Partners with Liquid Biosciences to Leverage the Power of Artificial Intelligence for the Expansion and Optimization of Biomarker Selection for PancAlert
    From Mainz BioMed NV
    Via GlobeNewswire
    Early Cancer Detection Saves Lives - This Biotech Has A Promising New Test
    Via News Direct
    Mainz Biomed Seeks FDA Approval For Colorectal Cancer Test It Says Is Nearly Twice As Sensitive As Others – A Look At Pipeline And Milestones
    Via News Direct
    Exposures Product Safety
    Mainz Biomed's (NASDAQ: MYNZ) Cutting-Edge Colorectal Cancer Test Applies For FDA Breakthrough Status
    Via News Direct
    Topics Artificial Intelligence
    Exposures Artificial Intelligence Product Safety
    Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
    Via Benzinga
    Exposures COVID-19
    Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
    From Mainz BioMed NV
    Via GlobeNewswire
    Pfizer And Mainz Provide Examples Of Using Emerging Technology For Good
    Via Benzinga
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.